AbbVie Inc. (BIT:1ABBV)

Market Cap	269.11B
Revenue (ttm)	54.41B
Net Income (ttm)	4.09B
Shares Out	n/a
EPS (ttm)	2.31
PE Ratio	65.74
Forward PE	n/a
Dividend	4.29 (2.82%)
Ex-Dividend Date	Apr 14, 2025

Volume	2
Average Volume	76
Open	151.60
Previous Close	153.60
Day's Range	151.60 - 152.40
52-Week Range	143.04 - 202.55
Beta	n/a
RSI	26.75
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD